Totals of 84 patients (91 eyes) in 2002 and 41 patients (43 eyes) in 2008 were identified with incident neovascular AMD and longer than 12 months of follow-up. Twenty-six of 91 eyes (29%) in the 2002 cohort and 3 of 43 eyes (7%) in the 2008 cohort had follow-up less than 19 months, for which 2-year data were imputed. Subsequent to 12 months following treatment initiation, most patients had stable vision. Two-year outcomes were analyzed with and without imputed data and no substantive differences were apparent. Baseline characteristics in the 2 cohorts appeared comparable with respect to mean age (77 years in 2002, 76 years in 2008), gender (39% women in both cohorts), and prevalence of neovascular AMD in the fellow eye (45% in both cohorts). Mean baseline VA in the study eye was slightly worse in 2002 (20/80; 95% CI, 20/50-20/125) than in 2008 (20/63; 95% CI, 20/32-20/80), for which results were adjusted using multivariable logistic regression in reported data. Forty of 41 patients (98%) in the 2008 cohort received anti-VEGF therapy. This therapy was not available for the 2002 group, who were managed using photodynamic therapy, laser photocoagulation, or observation. The Table shows the 2-year prevalence of legal blindness, mild and moderate visual impairment in both cohorts, the 2-year prevalence of visual impairment in the study eye, and the relative odds of outcomes adjusted for age, gender, and baseline VA in the study eye.